The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

This Phase II, randomized, double-blind, placebo-controlled dose-ranging, parallel and adaptive study aims to evaluate the efficacy and safety of enpatoran in SLE and in CLE (SCLE and/or DLE) participants receiving standard of care (WILLOW).

To Learn More Contact:

EMD Serono US Medical Information at 888-275-7376 or email at

Communications Center by phone at +49 6151 72 5200 or email at identifier (NCT number): NCT05162586

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up